Suchergebnisse - "Ding, Jian"

PubPharm (76)

1

A Novel IRAK4 Inhibitor DW18134 Ameliorates Peritonitis and Inflammatory Bowel Disease

enthalten in: Molecules (Basel, Switzerland) | 2024

von Huang, Y. | Ning, Y. | Chen, Z. | +13

2

Tetrandrine synergizes with MAPK inhibitors in treating KRAS-mutant pancreatic ductal adenocarcinoma via collaboratively modulating the TRAIL-death receptor axis

enthalten in: Pharmacological research | 2023

von Tang, S. | Duan, Y. | Yuan, T. | +14

3

SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer

enthalten in: Signal transduction and targeted therapy | 2023

von Zhou, J. | Zhang, X. | Xue, S. | +16

4

Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations

enthalten in: Journal of medicinal chemistry | 2022

von Chen, H. | Lai, M. | Zhang, T. | +9

5

LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo

enthalten in: Cancer science | 2022

von Liu, Y. | Lai, M. | Li, S. | +20

6

18F-FDG PET as an imaging biomarker for the response to FGFR-targeted therapy of cancer cells via FGFR-initiated mTOR/HK2 axis

enthalten in: Theranostics | 2022

von Jiang, Y. | Zeng, Q. | Jiang, Q. | +13

7

Discovery and structure - activity relationship exploration of pyrazolo[1,5-a]pyrimidine derivatives as potent FLT3-ITD inhibitors

enthalten in: Bioorganic & medicinal chemistry | 2021

von Chen, Y. | Bai, G. | Li, Y. | +7

8

A novel tricyclic BTK inhibitor suppresses B cell responses and osteoclastic bone erosion in rheumatoid arthritis

enthalten in: Acta pharmacologica Sinica | 2021

von Liu, Y. | Ding, H. | Lin, Z. | +15

9

DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo

enthalten in: Acta pharmacologica Sinica | 2021

von Dai, M. | Wang, Y. | Fan, J. | +9

10

SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors

enthalten in: Acta pharmacologica Sinica | 2021

von Xia, Z. | Ji, Y. | Sun, D. | +8

1
2
3
4
5
6
7
8
Nächster »
[8]